^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    20h
    A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Chinese PLA General Hospital
    New P2 trial • pMMR
    |
    AiRuiKa (camrelizumab) • capecitabine • oxaliplatin
    1d
    Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P3, N=556, Recruiting, Sun Yat-sen University
    New P3 trial
    |
    MSI (Microsatellite instability)
    |
    capecitabine • oxaliplatin • Puyouheng (pucotenlimab)
    1d
    Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial (clinicaltrials.gov)
    P2, N=165, Not yet recruiting, Fudan University
    New P2 trial • pMMR
    |
    MSI (Microsatellite instability)
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab)
    1d
    Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin (clinicaltrials.gov)
    P=N/A, N=274, Recruiting, Qianfoshan Hospital | Enrolling by invitation --> Recruiting | N=196 --> 274 | Trial completion date: Dec 2026 --> Jul 2027 | Trial primary completion date: Dec 2026 --> Jul 2027
    Enrollment status • Enrollment change • Trial completion date • Trial primary completion date
    1d
    Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Pei-Rong Ding | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan
    1d
    Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Guangdong Provincial People's Hospital
    New P2 trial • pMMR
    |
    AiRuiKa (camrelizumab) • capecitabine • Onivyde (nanoliposomal irinotecan)
    1d
    Registry Maastro Applicator (clinicaltrials.gov)
    P=N/A, N=999, Recruiting, Maastricht Radiation Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Providence Health & Services | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    CRP (C-reactive protein)
    |
    capecitabine • galunisertib (LY2157299) • fluorouracil topical
    1d
    Current status and future perspectives of precision treatment for locally advanced rectal cancer (PubMed, Beijing Da Xue Xue Bao Yi Xue Ban)
    Collectively, these advances are driving locally advanced rectal cancer management towards a "biologically-driven" and "function-preserving" model. Future efforts must focus on establishing standardized protocols for these technologies and validating their long-term benefits in survival and quality of life through high-quality, multi-center clinical trials.
    Review • Journal • MSi-H Biomarker • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    2d
    TRI-LARC: Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1/2, N=94, Terminated, Cancer Trials Ireland | Phase classification: P2 --> P1/2
    Phase classification
    3d
    Development and internal validation of a prognostic nomogram for lung metastasis in locally advanced rectal cancer incorporating molecular markers. (PubMed, Transl Cancer Res)
    We identified the risk factors for lung metastasis in LARC patients treated with nCRT and TME and developed a nomogram to facilitate individualized imaging and follow-up strategies. Further studies with larger sample size and external validation are warranted.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    3d
    REACT: ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer (clinicaltrials.gov)
    P3, N=103, Recruiting, Erasmus Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    5-fluorouracil • capecitabine • oxaliplatin